Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2016

View Archived Issues

Alder Biopharmaceuticals initiates PROMISE 2 phase III trial

Walter Reed Army Institute of Research presents promising new malaria vaccine candidates

Ariad Pharmaceuticals patents EGFR and/or HER2 mutant inhibitors

Roche discloses HTRA1 inhibitors

Hangzhou Hertz Pharmaceutical develops BTK inhibitors

Pharmalink's Nefecon earns orphan drug designation in E.U. for IgAN

Novan reports topline results from phase II study of SB-206

Cosmo reports on phase III trial of Zemcolo for travelers' diarrhea

BromSite launched in U.S.

Idelvion launched in Japan

Ustekinumab treatment shows promise in giant cell arteritis

Cerecor reports topline data from phase II trial of CERC-301 in major depressive disorder

BLA for avelumab accepted by FDA for priority review

VBL Therapeutics reports overall survival data from phase II trial of VB-111

Results of AEGIS-I trial of CSL-112

Celldex Therapeutics completes Kolltan acquisition

QLT changes name to Novelion Therapeutics following merger with Aegerion

Evotec and Merck KGaA to collaborate on target discovery technologies

FDA grants rare pediatric disease designation to Vtesse's VTS-270

IL-1 blockade with anakinra evaluated for CPPD crystal arthritis

Arrowhead discontinues EX1-containing programs

OncoQuest reports promising interim data from phase IIb study of oregovomab in ovarian cancer

BioVie submits IND to FDA for drug to treat ascites due to liver cirrhosis

Tolerability, pharmacokinetics reported for AMG-232 in first-in-human cancer trial

EMA accepts Coherus BioSciences' MAA for pegfilgrastim biosimilar

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...